Baker Bros. Advisors (GP) LLC's Net Worth

$1.77 Billion

Who is Baker Bros. Advisors (GP) LLC?

Baker Bros. Advisors (GP) LLC has an estimated net worth of $1.77 Billion. This is based on reported shares across multiple companies, which include Seagen Inc., RHYTHM PHARMACEUTICALS, INC., BeiGene, Ltd., INCYTE CORP, Invitae Corp, Prelude Therapeutics Inc, XOMA Corp, Kiniksa Pharmaceuticals, Ltd., Mirati Therapeutics, Inc., Zymeworks Inc., Intellia Therapeutics, Inc., Entrada Therapeutics, Inc., IGM Biosciences, Inc., Kodiak Sciences Inc., ACADIA PHARMACEUTICALS INC, BIOCRYST PHARMACEUTICALS INC, IDERA PHARMACEUTICALS, INC., DBV Technologies S.A., TScan Therapeutics, Inc., Neoleukin Therapeutics, Inc., Atreca, Inc., Aeglea BioTherapeutics, Inc., BELLICUM PHARMACEUTICALS, INC, HOOKIPA Pharma Inc., Talis Biomedical Corp, ALEXION PHARMACEUTICALS, INC., MADRIGAL PHARMACEUTICALS, INC., SYNAGEVA BIOPHARMA CORP, GENOMIC HEALTH INC, and Principia Biopharma Inc..

SEC CIK

Baker Bros. Advisors (GP) LLC's CIK is 0001580575

Past Insider Trading and Trends

2016 was Baker Bros. Advisors (GP) LLC's most active year for acquiring shares with 455 total transactions. Baker Bros. Advisors (GP) LLC's most active month to acquire stocks was the month of April. 2019 was Baker Bros. Advisors (GP) LLC's most active year for disposing of shares, totalling 379 transactions. Baker Bros. Advisors (GP) LLC's most active month to dispose stocks was the month of October. 2013 saw Baker Bros. Advisors (GP) LLC paying a total of $53,602,564,871.66 for 542,479,071 shares, this is the most they've acquired in one year. In 2013 Baker Bros. Advisors (GP) LLC cashed out on 117,319,500 shares for a total of $49,999,437,165.60, their largest year based on trade value.